Literature DB >> 29692394

Protection from Preeclampsia.

Antonio Ponzetto1, Natale Figura2, Annalisa Santucci3.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29692394      PMCID: PMC5937332          DOI: 10.4103/0366-6999.230741

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


× No keyword cloud information.
To the Editor: We appreciated the attentive and interesting paper by Huai et al.[1] on the protective effects of pravastatin on preeclampsia (PE)-like effects in mouse models. We would like to remind that PE is the first cause of illness and death for pregnant women and their children worldwide, the highest prevalence being in South America. Hence, every measure capable of preventing or averting the full-blown eclampsia is very welcomed. In mice, Helicobacter pylori infection exerted a negative effect upon pregnancy; in humans, Eslick et al.[2] observed fetal intrauterine growth restrictions in newborns from mothers infected with H. pylori. This bacterium was also shown to be an independent risk factor for cerebral ischemia of atherothrombotic origin. Therefore, we reasoned that the cerebral ischemia typically occurring in PE could be associated with the infection by this pathogen. Indeed, we and others found it to be the case;[3] in Turin, Italy, 90.6% of fetal intrauterine growth restrictions occurred in newborns from PE mothers carrying pathogenic strains of H. pylori with an odd ratio of 54.97 (95% confidence interval: 9.24–326.88), compared to noncytotoxin-associated gene A (cagA) strain-infected mothers.[4] These strains are characterized by the presence of the cagA coding for the CagA protein that is endowed with an increased inflammatory potential. For example, the infection in mouse by CagA-expressing strains induces a Th1-type response even at the level of the endometrium. Such phenomenon would downregulate the secretion of cytokines produced by Th2 immunocytes, which enable fetal survival. Not surprisingly, South American countries have a very high prevalence of both PE and H. pylori infection, whose long-term consequence, i.e., gastric cancer, still is the first cause of cancer death in Peru and Colombia, the second in Mexico and Brazil, as well as in Japan. Referring to possible causes of ischemia, H. pylori was shown to bind von Willebrand factor and to interact with glycoprotein Ib to induce platelet aggregation;[5] not only, but both in mice and in humans, H. pylori infection causes platelets activation and that of endothelial cells. All of the above is present in the preeclamptic state that could eventually lead to the full-blown eclampsia. We believe that it would be prudent to add H. pylori in the workup of pregnancy tests.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Helicobacter pylori's virulence and infection persistence define pre-eclampsia complicated by fetal growth retardation.

Authors:  Simona Cardaropoli; Alessandro Rolfo; Annalisa Piazzese; Antonio Ponzetto; Tullia Todros
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

2.  Pre-eclampsia is associated with Helicobacter pylori seropositivity in Italy.

Authors:  Antonio Ponzetto; Simona Cardaropoli; Ettore Piccoli; Alessandro Rolfo; Luisa Gennero; Darja Kanduc; Tullia Todros
Journal:  J Hypertens       Date:  2006-12       Impact factor: 4.844

3.  Foetal intrauterine growth restrictions with Helicobacter pylori infection.

Authors:  G D Eslick; P Yan; H H-X Xia; H Murray; B Spurrett; N J Talley
Journal:  Aliment Pharmacol Ther       Date:  2002-09       Impact factor: 8.171

4.  Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation.

Authors:  Michael F Byrne; Steven W Kerrigan; Paul A Corcoran; John C Atherton; Frank E Murray; Desmond J Fitzgerald; Dermot M Cox
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682

5.  Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models.

Authors:  Jing Huai; Zi Yang; Yan-Hong Yi; Guang-Jiao Wang
Journal:  Chin Med J (Engl)       Date:  2018-02-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.